Pulse Biosciences Stock Today
| PLSE Stock | USD 17.80 0.39 2.24% |
Performance4 of 100
| Odds Of DistressLess than 6
|
Pulse Biosciences is trading at 17.80 as of the 2nd of January 2025, a 2.24 percent increase since the beginning of the trading day. The stock's lowest day price was 17.25. Pulse Biosciences has only a 6 % chance of going through financial distress over the next few years but had a somewhat insignificant performance during the last 90 days. The performance scores are derived for the period starting the 12th of July 2023 and ending today, the 2nd of January 2025. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 18th of May 2016 | Category Healthcare | Classification Health Care |
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California. Pulse Biosciences operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. The company has 61.52 M outstanding shares of which 2.17 M shares are at this time shorted by private and institutional investors with about 21.18 trading days to cover. More on Pulse Biosciences
Moving against Pulse Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Pulse Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Kevin Danahy | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Health Care Equipment & Supplies, Medical Instruments & Supplies, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsPulse Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Pulse Biosciences' financial leverage. It provides some insight into what part of Pulse Biosciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pulse Biosciences (PLSE) is traded on NASDAQ Exchange in USA. It is located in 3957 Point Eden Way, Hayward, CA, United States, 94545 and employs 56 people. Pulse Biosciences is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 992.88 M. Pulse Biosciences conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 61.52 M outstanding shares of which 2.17 M shares are at this time shorted by private and institutional investors with about 21.18 trading days to cover.
Pulse Biosciences currently holds about 14.8 M in cash with (33.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.4.
Check Pulse Biosciences Probability Of Bankruptcy
Ownership AllocationPulse Biosciences owns a total of 61.52 Million outstanding shares. Pulse Biosciences holds majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 71.93 pct. of Pulse Biosciences outstanding shares that are owned by insiders implies they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Pulse Ownership Details
Pulse Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Westside Investment Management, Inc. | 2024-09-30 | 55 K | |
| Bank Of New York Mellon Corp | 2024-09-30 | 40.3 K | |
| Spotlight Asset Group, Inc. | 2024-06-30 | 40.3 K | |
| Swiss National Bank | 2024-09-30 | 35.9 K | |
| Goldman Sachs Group Inc | 2024-09-30 | 35.7 K | |
| Ubs Asset Mgmt Americas Inc | 2024-09-30 | 33.5 K | |
| Barclays Plc | 2024-09-30 | 30.3 K | |
| Tiaa Trust National Association | 2024-09-30 | 27.3 K | |
| Rhumbline Advisers | 2024-09-30 | 25.8 K | |
| Blackrock Inc | 2024-06-30 | 1.1 M | |
| Vanguard Group Inc | 2024-09-30 | 995.8 K |
Pulse Biosciences Historical Income Statement
Pulse Stock Against Markets
Pulse Biosciences Corporate Management
| Patty Perla | Vice Resources | Profile | |
| Sandra Gardiner | CFO Admin | Profile | |
| JD Esq | General Secretary | Profile | |
| Gansevoort MD | Chief Officer | Profile | |
| Niv MD | Chief Surgery | Profile | |
| Richard Nuccitelli | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulse Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Pulse Stock refer to our How to Trade Pulse Stock guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulse Biosciences. If investors know Pulse will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulse Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Pulse Biosciences is measured differently than its book value, which is the value of Pulse that is recorded on the company's balance sheet. Investors also form their own opinion of Pulse Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Pulse Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulse Biosciences' market value can be influenced by many factors that don't directly affect Pulse Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulse Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulse Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulse Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.